October 22, 2009
Phase 2a study of AR-12286 for treatment of glaucoma and ocular hypertensionAerie Pharmaceuticals announced positive results from a Phase 2a study of AR-12286 for the treatment of primary open angle glaucoma or ocular hypertension. This multicenter, randomized, double-masked, placebo-controlled study involved 88 patients with primary open angle glaucoma or ocular hypertension. Patients were randomized to receive one of three doses of AR-12286 or placebo. Patients were first dosed once daily and then twice daily and evaluated over a three-week treatment period. In the study, AR-12286 achieved statistical significance in lowering intraocular pressure (IOP) with both once-daily and twice-daily treatment. AR-12286 achieved a maximum change of mean IOP of 28% from baseline, which is comparable to, or exceeds, pressure lowering attained by the most commonly used glaucoma drugs as reported in other studies.
AR-12286 is a highly selective Rho-kinase (ROCK) inhibitor designed to lower IOP by improving outflow of fluid via the trabecular pathway. This class of compounds acts directly on diseased tissue, the trabecular meshwork (TM), which undergoes pathological changes in patients with primary open angle glaucoma. Altered TM morphology eventually restricts the drainage of fluid from the eye, causing an increase in IOP and ultimately damage to the optic nerve. ROCK inhibitors return the TM to a state that allows normal drainage of ocular fluid and thereby reduces pressure in the eye.
For more information call (908) 685-0069 or visit www.aeriepharma.com.